VACH
Voyager Acquisition Corp./Cayman Islands
Key Financials
Operating Income
$-1785259
↓ 154.0%
Net Income
$9.0M
↑ 117.1%
Total Liabilities
$13.3M
↑ 10.4%
Shareholders' Equity
$-13145478.00
↓ 15.6%
EPS (Diluted)
$0.24
↑ 100.0%
Total Assets
$270.1M
↑ 3.9%
Cash & Equivalents
$668285.00
N/A
Operating Cash Flow
$-486182.00
↑ 30.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 4/15/2026 | View on SEC |
| 10-K/A | 4/2/2026 | View on SEC |
| 425 | 3/18/2026 | View on SEC |
| 8-K | 3/18/2026 | View on SEC |
| 425 | 3/12/2026 | View on SEC |
| 10-K | 3/10/2026 | View on SEC |
| 8-K | 2/27/2026 | View on SEC |
| 425 | 2/27/2026 | View on SEC |
| 424B3 | 2/19/2026 | View on SEC |
| EFFECT | 2/17/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | VACH |
| Company Name | Voyager Acquisition Corp./Cayman Islands |
| CIK | 2006815 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | E9 |
| Phone | 03477204333 |